A Kopp-Schneider
Overview
Explore the profile of A Kopp-Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
941
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glemser P, Rotkopf L, Ziener C, Beuthien-Baumann B, Weru V, Kopp-Schneider A, et al.
Cancer Imaging
. 2022 Sep;
22(1):53.
PMID: 36138437
Aim: To compare [Ga]PSMA-11 PET-CT, [Ga]PSMA-11 PET-MRI and MRI in a cohort of prostate cancer (PCa) patients in biochemical recurrence after initial curative therapy. Materials And Methods: Fifty-three patients with...
2.
Holland-Letz T, Kopp-Schneider A
Toxicol Lett
. 2020 Nov;
337:18-27.
PMID: 33232777
Background And Objective: Optimal experimental design theory proposes choosing specific settings in experimental trials in order to maximize the precision of the resulting parameter estimates. In dose response experiments, this...
3.
Sachpekidis C, Goldschmidt H, Kopka K, Kopp-Schneider A, Dimitrakopoulou-Strauss A
EJNMMI Res
. 2018 Apr;
8(1):28.
PMID: 29633046
Background: Despite the significant upgrading in recent years of the role of F-FDG PET/CT in multiple myeloma (MM) diagnostics, there is a still unmet need for myeloma-specific radiotracers. 3'-Deoxy-3'-[F]fluorothymidine (F-FLT)...
4.
Sachpekidis C, Baumer P, Kopka K, Hadaschik B, Hohenfellner M, Kopp-Schneider A, et al.
Eur J Nucl Med Mol Imaging
. 2018 Jan;
45(6):904-912.
PMID: 29362859
Purpose: The aims of this retrospective analysis were to compare Ga-PSMA PET findings and low-dose CT findings (120 kV, 30 mA), and to obtain semiquantitative and quantitative Ga-PSMA PET data...
5.
Bickelhaupt S, Paech D, Laun F, Steudle F, Kuder T, Mlynarska A, et al.
Clin Radiol
. 2017 Jul;
72(10):900.e1-900.e8.
PMID: 28687167
Aim: To investigate an abbreviated, contrast-agent free diffusion-weighted (DW) breast magnetic resonance imaging (MRI) protocol that provides a single image for the radiologist to read in order to non-invasively examine...
6.
Dick J, Lang N, Slynko A, Kopp-Schneider A, Schulz C, Dimitrakopoulou-Strauss A, et al.
Immunotherapy
. 2016 Aug;
8(9):1033-44.
PMID: 27485076
Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation. Methods: In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated...
7.
Freitag M, Radtke J, Hadaschik B, Kopp-Schneider A, Eder M, Kopka K, et al.
Eur J Nucl Med Mol Imaging
. 2015 Oct;
43(1):70-83.
PMID: 26508290
Purpose: To evaluate the reproducibility of the combination of hybrid PET/MRI and the (68)Ga-PSMA-11 tracer in depicting lymph node (LN) and bone metastases of prostate cancer (PC) in comparison with...
8.
Vichi S, Sandstrom von Tobel J, Gemma S, Stanzel S, Kopp-Schneider A, Monnet-Tschudi F, et al.
Toxicol In Vitro
. 2015 Mar;
30(1 Pt A):176-84.
PMID: 25795400
Within the Predict-IV FP7 project a strategy for measurement of in vitro biokinetics was developed, requiring the characterization of the cellular model used, especially regarding biotransformation, which frequently depends on...
9.
Rettig I, Koeneke E, Trippel F, Mueller W, Burhenne J, Kopp-Schneider A, et al.
Cell Death Dis
. 2015 Feb;
6:e1657.
PMID: 25695609
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic acid and histone deacetylase (HDAC) inhibitors, are of particular interest. HDAC inhibitors are currently under investigation for the treatment of...
10.
Noack J, Choi J, Richter K, Kopp-Schneider A, Regnier-Vigouroux A
Cell Death Dis
. 2014 Sep;
5:e1425.
PMID: 25255218
Glioblastomas (GBMs) are very aggressive tumors with low chemosensitivity. The DNA-alkylating agent temozolomide (TMZ) is currently the most efficient chemotoxic drug for GBM therapy; however, many patients develop resistance to...